ArticleMolecular biology reports2021
Prophylactic effect of myricetin and apigenin against lipopolysaccharide-induced acute liver injury.
Article in Molecular biology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Flavonoids as Nutraceuticals to Treat Inflammatory Diseases: Focusing on Quercetin, Kaempferol, Luteolin, Apigenin, Epicatechin and Their Effects on Hepatic, Nervous, and Pulmonary Systems.Foods (Basel, Switzerland) · 2026Review
- [Petroleum ether fraction ofNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Myricetin alleviates testosterone-induced benign prostatic hyperplasia by attenuating inflammation, oxidative stress, apoptosis and androgen signaling.Scientific reports · 2026Article
- Unlocking the Pharmacological Potential of Myricetin Against Various Pathogenesis.International journal of molecular sciences · 2025Review
- The protective effects and mechanism of myricetin in liver diseases (Review).Molecular medicine reports · 2025Review
- Advances in Understanding Lipopolysaccharide-Mediated Hepatitis: Mechanisms and Pathological Features.Current issues in molecular biology · 2025Review
- Review
- COVID-19-Associated Sepsis: Potential Role of Phytochemicals as Functional Foods and Nutraceuticals.International journal of molecular sciences · 2024Review
- Boswellic Acid and Betulinic Acid Pre-treatments Can Prevent the Nephrotoxicity Caused by Cyclophosphamide Induction.Doklady. Biochemistry and biophysics · 2024Article
- Analyzing the molecular mechanism of Scutellaria Radix in the treatment of sepsis using RNA sequencing.BMC infectious diseases · 2024Article
- Apigenin: A Bioflavonoid with a Promising Role in Disease Prevention and Treatment.Biomedicines · 2024Review
- Apigenin as an emerging hepatoprotective agent: current status and future perspectives.Frontiers in pharmacology · 2024Review
- The anti-cholestatic effects ofFrontiers in pharmacology · 2024Article
- Myricetin attenuates hypoxia-induced inflammation in human adipocytes.Molecular biology reports · 2023Article
- Benefits of Some Phytochemical Compounds in Experimental Sepsis Models: A Therapeutic Perspective.The Eurasian journal of medicine · 2023Article
- Review
- Insights into the pharmacological and therapeutic effects of apigenin in liver injuries and diseases.Heliyon · 2023Article
- Effects of Herbs and Derived Natural Products on Lipopolysaccharide-Induced Toxicity: A Literature Review.Oxidative medicine and cellular longevity · 2023Review
- Study on the mechanism of acute liver injury protection in Rhubarb anthraquinone by metabolomics based on UPLC-Q-TOF-MS.Frontiers in pharmacology · 2023Article
- Beneficial Effects ofOxidative medicine and cellular longevity · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundLiver has an important role in the initiation and progression of multiple organ failure that occurs in sepsis. Many natural active substances can be used to reduce the liver injury caused by sepsis. For this aim, the effects of myricetin and apigenin on mice model of acute liver injury was evaluated in this study. METHODS AND
resultsThirty-six mice were randomly divided into six groups as; control, lipopolysaccharide (LPS) (5 mg/kg), LPS + myricetin (100 mg/kg), LPS + myricetin (200 mg/kg), LPS + apigenin (100 mg/kg), and LPS + apigenin (200 mg/kg) groups. Myricetin and apigenin were administered orally for 7 days, and LPS was administered intraperitoneally only on the 7th day of the study. 24 h after LPS application, all animals were sacrificed and serum biochemical parameters, histopathology and oxidative stress and inflammation markers of liver tissue were examined. Myricetin and apigenin pre-treatments increased serum albumin and total protein levels, liver GSH level and catalase and SOD activities and decreased serum ALT, AST, ALP, γ-GT, CRP, total and direct bilirubin levels, liver MPO activity, MDA, NOx, PGE
conclusionMyricetin and apigenin pre-treatments led to reduction of liver injury indices and oxidative stress and inflammatory events and these flavonoids has probably hepatoprotective effects in acute liver injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.